CA2645558C - Regulation of phospholipase d activity - Google Patents

Regulation of phospholipase d activity Download PDF

Info

Publication number
CA2645558C
CA2645558C CA2645558A CA2645558A CA2645558C CA 2645558 C CA2645558 C CA 2645558C CA 2645558 A CA2645558 A CA 2645558A CA 2645558 A CA2645558 A CA 2645558A CA 2645558 C CA2645558 C CA 2645558C
Authority
CA
Canada
Prior art keywords
carbon atoms
branched
inclusive
straight chain
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2645558A
Other languages
English (en)
French (fr)
Other versions
CA2645558A1 (en
Inventor
Charles N. Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA2768688A priority Critical patent/CA2768688A1/en
Publication of CA2645558A1 publication Critical patent/CA2645558A1/en
Application granted granted Critical
Publication of CA2645558C publication Critical patent/CA2645558C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2645558A 1999-03-18 2000-03-14 Regulation of phospholipase d activity Expired - Fee Related CA2645558C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2768688A CA2768688A1 (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12519499P 1999-03-18 1999-03-18
US60/125,194 1999-03-18
CA002365240A CA2365240C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002365240A Division CA2365240C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2768688A Division CA2768688A1 (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Publications (2)

Publication Number Publication Date
CA2645558A1 CA2645558A1 (en) 2000-09-21
CA2645558C true CA2645558C (en) 2012-05-15

Family

ID=22418604

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2645558A Expired - Fee Related CA2645558C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity
CA002365240A Expired - Fee Related CA2365240C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002365240A Expired - Fee Related CA2365240C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Country Status (10)

Country Link
US (5) US6353026B1 (https=)
EP (2) EP2236140A1 (https=)
JP (1) JP4392473B2 (https=)
AT (1) ATE466582T1 (https=)
AU (1) AU780114B2 (https=)
CA (2) CA2645558C (https=)
DE (1) DE60044335D1 (https=)
ES (1) ES2344138T3 (https=)
HK (1) HK1043306B (https=)
WO (1) WO2000054761A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US6745204B1 (en) * 1999-02-12 2004-06-01 Mount Sinai Hospital System for electronically managing, finding, and/or displaying biomolecular interactions
EP1153355A2 (en) * 1999-02-12 2001-11-14 Mount Sinai Hospital System for electronically managing, finding, and/or displaying biomolecular interactions
CA2675416A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
EP1586550A1 (en) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
JP4652685B2 (ja) * 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
CN101278053A (zh) 2005-07-29 2008-10-01 孟山都技术有限公司 利用来自转基因杂交体的分离子来开发新的种质
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
JP2009545527A (ja) * 2006-07-19 2009-12-24 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 粘膜炎の治療用の組成物及び方法
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
KR101306199B1 (ko) 2012-01-31 2013-09-09 부산대학교 산학협력단 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물
WO2014084866A1 (en) 2012-12-01 2014-06-05 Halliburton Energy Services, Inc. Protection of electronic devices used with perforating guns

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JPH08512023A (ja) * 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
CA2675416A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.

Also Published As

Publication number Publication date
CA2365240A1 (en) 2000-09-21
EP1162976B1 (en) 2010-05-05
US6864288B2 (en) 2005-03-08
HK1043306A1 (en) 2002-09-13
ES2344138T3 (es) 2010-08-19
US20080064751A1 (en) 2008-03-13
EP1162976A2 (en) 2001-12-19
US20020120013A1 (en) 2002-08-29
JP2002539156A (ja) 2002-11-19
ATE466582T1 (de) 2010-05-15
WO2000054761A9 (en) 2001-10-25
US6353026B1 (en) 2002-03-05
EP2236140A1 (en) 2010-10-06
HK1043306B (en) 2010-09-17
US20020107289A1 (en) 2002-08-08
WO2000054761A2 (en) 2000-09-21
CA2365240C (en) 2009-01-20
WO2000054761A3 (en) 2001-03-29
JP4392473B2 (ja) 2010-01-06
DE60044335D1 (de) 2010-06-17
US20050187294A1 (en) 2005-08-25
AU780114B2 (en) 2005-03-03
AU3745100A (en) 2000-10-04
US6927238B2 (en) 2005-08-09
CA2645558A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
CA2645558C (en) Regulation of phospholipase d activity
Levy et al. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a ‘stop’signaling switch for aspirin‐triggered lipoxin A4
AU2009201390B8 (en) A novel approach to antimicrobial host defense against gram-negative infections
CA2265708C (en) Lipoxin compounds and their use in treating cell proliferative disorders
ES2246230T3 (es) Compuestos de lipoxina y su utilizacion.
WO2008058274A2 (en) Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
Dew et al. Effects of pharmacological retinoids on several vitamin A-metabolizing enzymes
AU2009208104B2 (en) Regulation of phospholipase D activity
AU2005202416B2 (en) Regulation of phospholipase D activity
CA2768688A1 (en) Regulation of phospholipase d activity
AU2012203490A1 (en) Regulation of phospholipase D activity
US5567729A (en) Farnesyl compounds as farnesyl protein transferase inhibitors to treat ras induced tumor growth
Spokas et al. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids
NAGATA et al. Effects of simvastatin (MK-733) on branched pathway of mevalonate
EP1941875B1 (en) Use of lipoxin analogs to promote cell defense against gram-negative infections
Recchiuti et al. Lipoxins, resolvins, and the resolution of inflammation
Jondal et al. The lipoxygenase pathway in the human NK cell system
HK1161556A (en) Use of lipoxin analogs to promote cell defense against gram-negative infections
OH hydroxy-5 (6)-oxido-7, 9, 13-trans-11-cis-eicosatetraenoic acid. The stereochemistry of all of the compounds shown has been determinedl1, 12.
DAVID Effects of Lithium on Essential Fatty Acid and Prostaglandin Metabolism

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150316